Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.38 |
| ▸ | CCNK | O75909 | 5/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.36 |
| ▸ | CDK2 | P24941 | 5/20 | 0.36 |
| ▸ | CDK12 | Q9NYV4 | 5/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 3/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.33 |
| ▸ | AR | P10275 | 3/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | CCR6 | P51684 | 2/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | F2R | P25116 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1936695 | 1.00 | GPR65 (0.38) | GPR65CCNKCCNA2CDK2CDK12 | |
| SCHEMBL1937258 | 0.85 | GAA (0.37) | CCNKCCNA2CDK2CDK12CTSK | |
| SCHEMBL1937259 | 0.85 | GAA (0.37) | CCNKCCNA2CDK2CDK12CTSK | |
| SCHEMBL1935663 | 0.83 | MAPK8 (0.37) | CCNKCCNA2CDK2CDK12HCAR3 | |
| SCHEMBL1935664 | 0.83 | MAPK8 (0.37) | CCNKCCNA2CDK2CDK12HCAR3 | |
| SCHEMBL1937156 | 0.82 | ACHE (0.41) | ACHE | |
| SCHEMBL1937158 | 0.82 | ACHE (0.41) | ACHE | |
| SCHEMBL1936985 | 0.81 | ACHE (0.40) | ACHE | |
| SCHEMBL1936984 | 0.81 | ACHE (0.40) | ACHE | |
| SCHEMBL31042430 | 0.80 | CTSK (0.45) | GPR65CDK2CTSKHCAR3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166161-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2011-07-07 | — | — | US | disclosed |
| EP-2331507-A2 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS | Astellas Pharma Inc. (JP) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010032875-A2 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166161-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS | ROCK1, ROCK2, RHOT2 | GPR65 588/4885CCNK 3148/4885CCNA2 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.